List of Therapeutic Companies in Poland - 13

Adamed Pharma is a Polish pharmaceutical and biotechnology company that was established thanks to its own scientific thought and its own patents. Currently, it produces approximately 500 products offered to patients in 78 countries around the world. It has representative offices in Spain, Russia, the Czech Republic, Vietnam, Italy, Kazakhstan, Uzbekistan, Slovakia and Ukraine. It currently employs approximately 2,400 people. The company has been conducting its own innovative research and development activities for over 20 years. It cooperates with leading universities and research institutes in Poland and abroad. The company's intellectual property is protected by over 200 patents in most countries around the world. Adamed also owns a controlling stake in Dat Vi Phu, one of the fastest growing local pharmaceutical companies in Vietnam. This transaction was the largest direct Polish investment in Vietnam so far. In 2019, Adamed acquired a block of shares in the Italian company Ecupharma, operating in the field of neuropsychiatry and urology.

Bioton S.A. - European Biotech Company producing human insulin: API and finished forms in cartridges and vials. For more than 20 years, we have been providing people with diabetes with efficacious and safe medicines. Bioton S.A. is an unquestionable leader on the Polish market, and in the world’s top eight commercial manufacturers of recombinant human insulin. Bioton S.A. continuously invests in the development of Polish biotechnology. We were the first company in Poland which, in cooperation with one of Polish scientific institutes, managed to commercialize the results of the Biotech Transfer. We apply the most current therapeutic and technological solutions to alleviate diabetes treatment for patients. We strive to build comprehensive solutions for the prevention and treatment of diabetes. Bioton S.A. offers CMO/CDMO and QC services. Our activities are based on QbD in line with cGMP standards. Bioton S.A. supplies also a range of innovative gastroenterological FSMP (Foods for Special Medical Purposes).

At Cellis, we are at the forefront of cell-based oncology therapy, specializing in innovative solutions for the treatment of solid tumors. We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC), which leverages the revolutionary TRAIN mechanism. This biologic discovery enables the efficient and highly targeted delivery of active compounds directly into the cytoplasm of cancer cells, leading to cell death and tumor shrinkage. MDC also reshapes the tumor microenvironment, fostering immune resistance to cancer growth. Our intellectual property is protected through PCT patent applications, with additional filings pending. As we prepare for first-in-human clinical trials in Q2 2025, we continue to push the boundaries of cancer treatment through integrated therapeutic and diagnostic solutions.

Cellivia is a biotechnology company specializing in: • cell and tissue bioengineering, biotechnology and biomedicine research - own and commercial projects • development and commercialization of innovative therapies and personalized medicines via exosomes • biological material banking for research purposes • bioengineering and robotics in medicine Our mission is to provide personalized medicines and medical therapies based on exosomes. Cellivia‘s team are high-class specialists, including scientists with the professor title, in the field of dentistry, cellular and molecular biology, biotechnology as well as chemical and material bioengineering. The company cooperates with leading universities and research centers in Europe such as the Poznan Science and Technology Park, the Poznan Medical University, the University Hospital and Masaryk University in Brno, Wielkopolska Center for Advanced Technologies. Cellivia conducts a number of research projects, such as the Oral Biology Project - research on the gum and pulp of human teeth; Animal Biology Project - research on animal material from the mucous membrane; Bioexofold - research on biologically active material for reconstruction and regeneration; Bioactive Abutment - research on functionalized titanium. Research projects are used in implemented therapies. The company also carries out pioneering research on chemical and material bioengineering in cooperation with the Poznan Science and Technology Park. Research includes developing a biologically active coating for use in implantology and prosthetics. We have applied for a patent Our Our innovative solutions are being reviewed by Patent Office Cellivia branches: CelliviaLab - area of research and laboratory activities CelliviaDent - the area of dental activity Cellivia Bank - a bank of stem cells and cell lines run for the needs of applied therapies - during the registration procedure

Our mission is to deliver mRNA technology innovations to revolutionize future therapies and the prevention of many diseases. We invent, develop, manufacture and apply our solutions for the benefit of pharmaceutical partners, and to improve people’s lives. With passion, ExploRNA Therapeutics develops ground-breaking innovations of mRNA as a therapeutic platform, applies those solutions in unique therapeutic programs, and delivers technology, therapeutic platform, and therapies to pharmaceutical partners.

IBSS BIOMED S.A. – an expert in vaccines and probiotics – is a Polish biotechnology company operating continuously since 1945. We make exceptional products, which are the effects of the synergy of our experience and the knowledge of reputable research institutes and modern technologies. For over 65 years, we have enjoyed the trust of patients, physicians and business partners. The basis of IBSS BIOMED S.A.'s activity is the production of: probiotics, vaccines (also those included in the Preventive Immunization Schedule), dietary supplements, allergens, as well as diagnostic preparations, media and indicators. We are known for innovative solutions and inventive ideas, which allow us to maintain the highest quality of the manufactured products and, as a result, satisfy customers' expectations. The company constantly improves its products so that they meet quality and market requirements, and are compliant with the highest standards of modern pharmaceutics by: introducing new manufacturing technologies, research methods, modernising the equipment of our laboratories. The areas of the company's activity: Production (own, contract manufacturing and research) R&D of the company's own products (clinical trials, registration) Sales and marketing Export/import

JJP Biologics is an innovative Polish biotechnology company developing novel biological therapies around established companion diagnostics. Our range of programs are in early stage development and we are actively seeking to cooperate with investors and academics on new or existing projects.

Polish medtech startup ONGENO has a therapy developed by Dr. Wojciech Orlowski, M.D., which has been proven in the first phase of the experiment to lead to improved sclerosis patient health, reduced disability, and lack of disease progression in the long term.

PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.

Proteon Pharmaceuticals S.A. uses precision biology for microbiome modulation to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics. PROTEON's products improve the economic efficiency in livestock farming and aquaculture, increasing environmental sustainability with natural products that also enhance animal welfare.

Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based on our own technology platforms for the selection of active molecules – antibodies and aptamers. Pure Biologics also offers commercial partnership options in several areas including early phase biological drug discovery and development, selection and characterisation of antibodies and aptamers, as well as protein production, purification and analysis.

Ryvu Therapeutics is a clinical stage biopharmaceutical company developing novel small molecule therapies addressing high value emerging targets in cancer and other serious diseases.

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.